Q3 2025 Bio Rad Laboratories Inc Earnings Call Transcript
Key Points
- Bio-Rad Laboratories Inc (BIO) achieved margin outperformance for the quarter through disciplined cost management and tight control of discretionary spending.
- The company made meaningful progress in advancing its Droplet Digital PCR strategy, with positive customer receptivity to new QX platforms.
- Bio-Rad Laboratories Inc (BIO) expanded its ddPCR-based diagnostic strategy through key partnerships with Gencurix and Biodesix, enhancing its commercial footprint in Europe and access to biomarker testing.
- The process chromatography business experienced strong double-digit growth year-over-year, contributing positively to the life sciences segment.
- Bio-Rad Laboratories Inc (BIO) maintained its 2025 full-year outlook, with expectations of a slight revenue improvement in the fourth quarter and sequential improvement in operating margins.
- The life sciences segment faced a 1.5% decrease on a currency-neutral basis due to constrained academic research and biotech funding environments.
- The clinical diagnostic segment experienced a decrease in sales on a currency-neutral basis, primarily due to lower reimbursement rates for diabetes testing in China.
- Gross margins decreased compared to the previous year, attributed to higher material costs and reduced fixed manufacturing absorption.
- Free cash flow for the third quarter decreased to $89 million from $123 million in the same period last year.
- The company faces ongoing challenges in the academic research market, with continued weak instrument demand and cautious customer spending due to funding uncertainties.
Ladies and gentlemen, thank you for standing by. My name is Desiree, and I will be your conference operator today. At this time, I would like to welcome everyone to the Bio-Rad third-quarter 2025 results conference call and webcast. (Operator Instructions)
I would now like to turn the conference over to Edward Chung, Head of Investor relations. You may begin.
Good afternoon, everyone, and thank you for joining us. Today, we will review the third quarter of 2025 financial results and provide an update on key business trends for Bio-Rad. With me on the call today are Norman Schwartz, our Chief Executive Officer; John DiVincenzo, President and Chief Operating Officer; and Roop Lakkaraju, Executive Vice President and Chief Financial Officer.
Before we begin our review, I would like to remind everyone that we'll be making forward-looking statements about management's goals, plans and expectations, our future financial performance, and other matters. These statements are
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
